Marc Ansseau
About
In The Last Decade
Marc Ansseau
127 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Clinical Psychology 891
- Experimental and Cognitive Psychology 744
- Cognitive Neuroscience 634
- Social Psychology 592
- Psychiatry and Mental health 592
Countries citing papers authored by Marc Ansseau
This map shows the geographic impact of Marc Ansseau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Ansseau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Ansseau more than expected).
Fields of papers citing papers by Marc Ansseau
This network shows the impact of papers produced by Marc Ansseau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Ansseau. The network helps show where Marc Ansseau may publish in the future.
Co-authorship network of co-authors of Marc Ansseau
This figure shows the co-authorship network connecting the top 25 collaborators of Marc Ansseau. A scholar is included among the top collaborators of Marc Ansseau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Ansseau. Marc Ansseau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 104 | |
| 2 | Analysis and optimization of substitution treatment in Belgium (SUBANOP) | 5 |
| 3 | 5 | |
| 4 | Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine. | 2 |
| 5 | Méthode d’évaluation de l’efficacité des psychotherapies: impact de la neuroimagerie fonctionnelle. | 1 |
| 6 | 105 | |
| 7 | 64 | |
| 8 | [Lipids, depression and suicide]. | 61 |
| 9 | Les marqueurs biologiques dans les personnalites schizotypique et borderline | 0 |
| 10 | Serotonergic modulation of P300 | 5 |
| 11 | CNV in mood disorders | 5 |
| 12 | L'état de stress post-traumatique chez les brûlés : Une revue. | 1 |
| 13 | Clonidine test and MMPI scales in major depression | 3 |
| 14 | Contingent negative variation in psychopharmacology | 2 |
| 15 | Pilot study of flesinoxan, a 5-HT1A agonist, in major depression | 0 |
| 16 | Biological markers of depression : state of the art : proceedings of the International Congress on Biological Markers of Depression--State of the Art, held in Liège, Belgium, on 13-15 June, 1990 | 1 |
| 17 | Contingent negative variation and severity of depression | 3 |
| 18 | Evaluation de l'activité clinique de la fluoxetine (Prozac) selon "les étoiles de Liège" | 1 |
| 19 | 17 | |
| 20 | Relationship between vasopressin, neurophysin and ACTH, cortisol plasma levels in non suppressor patients during dexamethasone suppression tests. | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.